marketing-medtech

**Country:** Italy
**Founder:** Antonio Nunzio d'Angelo — Co-founder & CEO
**Background:** tech | verified: True — Technical/engineering background. Antonio Nunzio D'Angelo is an engineer by training: he studied at EPFL (École polytechnique fédérale de Lausanne / Federal Polytechnic School of Lausanne) and previously worked at the Istituto Italiano di Tecnologia (Italian Institute of Technology) before co-founding Medicud, a Rome-based medtech startup (founded 2020) that developed a mechanically-powered negative pressure wound therapy device (DRYUM). He is Co-founder & CEO. This is consistent with the claimed "tech" background.
**Stage / fundraise:** Early clinical-stage medtech, founded June 2020 (Rome). Post-seed, pre-Series A. Pre-revenue, pre-CE mark; ~6 employees per profiles. Anticipated market entry 2027 per company site. / Raised €1.3M oversubscribed seed in April 2025 (€766K equity + €575K non-dilutive), led by US fund CHMBR Partners with 50 Partners Capital Health and Business Angels des Grandes Écoles (BADGE). Total raised since inception ~€2.5M. A Series A is signaled for H1 2026 to support commercialization. ACTIVELY ON A FUNDING/REGULATORY PATH.
**Regulatory trigger:** DRYUM is classified Class IIa under EU MDR 2017/745 (Class II / 510(k) under FDA). The seed round is explicitly funding the regulatory process toward CE mark and FDA approval, plus a pivotal clinical trial in orthopedic surgery (THA/TKA, 59 patients, Ospedale Ferrero, Piedmont, Prof. Marco Schiraldi). Regulatory approval targeted for H1 2026. NOTE: device is non-electronic/manual, so IEC 62304 software-lifecycle obligations are minimal-to-none today.
**Email:** contact@medicud.it (confidence high) — Published on the official company website medicud.it as the general contact address. This is a generic inbox, not the founder's personal address. Note: candidate prompt listed medicud.com, but the live/operating site is medicud.it.
**LinkedIn:** https://it.linkedin.com/in/antonio-nunzio-d-angelo (founder); https://www.linkedin.com/company/medicud (company) **Website:**
**Score:** 6 -> Tier C
**Hook:** Congratulate Antonio on the oversubscribed €1.3M seed and the pivotal orthopedic trial. Be candid: with a non-electronic device and an engineer co-founder/CTO already on board, OmDev's "tech team + dedicated CTO" pitch is not an obvious fit today. The honest angle is forward-looking: when DRYUM adds any digital layer (a clinician-facing companion app, adherence/outcome tracking, registry data for the MDR clinical-evidence file, or a connected next-gen variant), OmDev can stand up that software with built-in IEC 62304 traceability and a signed SOUP register feeding the technical file — at a fixed monthly price ~3x cheaper than hiring a software team, with the client owning the code. Lead with the regulatory-evidence engine, not headcount.

---

## Founder & background
Antonio Nunzio d'Angelo — Co-founder & CEO. Materials-science & engineering graduate of EPFL Lausanne and former collaborator at the Istituto Italiano di Tecnologia; a deep-tech, not finance/insurance, founder ([LinkedIn](https://it.linkedin.com/in/antonio-nunzio-d-angelo), [EU-Startups](https://www.eu-startups.com/2023/01/meet-medicud-an-eit-health-innostars-awards-winner-interview-with-founder-and-ceo-antonio-dangelo/)). He was inspired by his father, a Rome surgeon, who couldn't give a high-risk patient affordable incisional NPWT. Co-founder Andrea Cazzulani is CTO (aerospace engineer, Sapienza); R&D adds biomedical-engineer talent ([medicud.it](https://medicud.it/)). Net: a technical founding team with a CTO already in seat — a headwind for OmDev's usual "no-CTO / thin dev team" angle.

## Funding & momentum
Raised a €1.3M oversubscribed seed in April 2025 (€766K equity + €575K non-dilutive), led by US fund CHMBR Partners with 50 Partners Capital Health and BADGE; ~€2.5M total since 2020 inception ([Tech.eu](https://tech.eu/2025/04/09/italian-medtech-medicud-raises-1-3m-for-wound-pressurising-device/), [Vestbee](https://www.vestbee.com/insights/articles/medicud-secures-1-3-m)). A Series A is flagged for H1 2026. Active capital and a clear regulatory deadline make this a live, momentum-positive account.

## Product & regulatory
DRYUM is a single-use, MANUAL (non-electronic) incisional negative-pressure wound-therapy device made from bio-sourced polymers, with 5 granted patents — a hardware/materials product, not SaMD ([Vestbee](https://www.vestbee.com/insights/articles/medicud-secures-1-3-m), [medicud.it](https://medicud.it/about-dryum/)). It is EU MDR Class IIa (FDA Class II / 510(k)); the round funds CE mark + FDA work and a pivotal orthopedic trial (THA/TKA, 59 patients, Ospedale Ferrero, Prof. Schiraldi), with approval targeted H1 2026 ([Tech.eu](https://tech.eu/2025/04/09/italian-medtech-medicud-raises-1-3m-for-wound-pressurising-device/)). Because the device has no embedded software, IEC 62304 obligations are minimal today.

## Pain & buying signals
The strongest signal is the regulatory clock (Class IIa technical file, CE by H1 2026) — but that is device/QMS work, not software-lifecycle work, and there is no disclosed app, sensor, data platform, or digital layer. With technical founders and a CTO in place, the core OmDev value props don't map cleanly. This is a weak-fit lead today; the realistic opening is future digital scope (companion app, outcomes/registry data feeding the MDR clinical-evidence file, or a connected next-gen DRYUM).

**Why OmDev fits:** Only if/when Medicud adds software. If they build a clinician companion app, an adherence/outcomes tracker, or registry data collection for their MDR clinical evidence, OmDev can deliver that software with IEC 62304 traceability and a signed SOUP register feeding the technical file — fixed monthly price ~3x cheaper than a software hire, client owns the code (OmDev does not certify). Approach is consultative and forward-looking, not a headcount sell; otherwise deprioritize.

---
**Sources:** https://tech.eu/2025/04/09/italian-medtech-medicud-raises-1-3m-for-wound-pressurising-device/ · https://www.vestbee.com/insights/articles/medicud-secures-1-3-m · https://medicud.it/ · https://medicud.it/about-dryum/ · https://it.linkedin.com/in/antonio-nunzio-d-angelo · https://www.linkedin.com/company/medicud · https://www.eu-startups.com/2023/01/meet-medicud-an-eit-health-innostars-awards-winner-interview-with-founder-and-ceo-antonio-dangelo/ · https://ala.associates/funding/medicud-secures-over-e1-3m-in-oversubscribed-seed-funding-round-to-initiate-pivotal-trial-of-innovative-wound-healing-device/